logo
Share SHARE
FONT-SIZE Plus   Neg

Bayer Submits Application For EU Marketing Authorization For Xarelto

Bayer HealthCare, a subgroup of Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK), said it has submitted an application for marketing authorization to the European Medicines Agency for the oral anticoagulant Xarelto (rivaroxaban) for the treatment of pulmonary embolism, or PE, and the prevention of recurrent deep vein thrombosis and PE in adults.

The submission is supported by data from the pivotal, global Phase III EINSTEIN-PE study. The EINSTEIN-PE study compared the oral single-drug approach of rivaroxaban 15 mg twice daily for three weeks followed by 20 mg once daily with the current standard of care, subcutaneous enoxaparin followed by a VKA.

According to the company, Rivaroxaban demonstrated efficacy comparable to that of the current standard therapy in reducing the primary endpoint of recurrent symptomatic Venous Thromboembolism, or VTE, a composite of symptomatic deep vein thrombosis and non-fatal or fatal PE. The overall bleeding rates were similar between the treatment groups, but importantly rivaroxaban was associated with significantly lower rates of major bleeding.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
BlackRock (BLK) said its iShares division has launched the iShares Short Maturity Municipal Bond ETF (MEAR). The move by iShares, the world's largest manager of exchange traded funds, is part of efforts to boost its lineup of fixed income ETFs. iShares Short Maturity Municipal Bond ETF is actively... The drought crisis in California will not abate any time soon despite the onset of a somewhat weak El Nino, endangering crops and putting farmers and others to hardship. German auto giant BMW has refuted reports it is in discussion with tech giant Apple Inc. (AAPL) related to the making of an electric car. BMW has clarified that its discussion with Apple was not related to building an electric car but were "regular talks," according to a report from Reuters. On...
comments powered by Disqus
Follow RTT